Toxicity and efficacy of combined stereotactic radiotherapy (SRT) and systemic targeted or immunotherapy

Toxicity and efficacy of combined stereotactic radiotherapy (SRT) and systemic targeted or immunotherapy - TOaSTT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015138

Enrollment

500

Registered

2019-06-06

Start date

2017-10-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78 C79

Interventions

Group 1: Routine data (in terms of patient, tumor and treatment characteristics, as well as toxicity and efficacy over 2 years) of patients with a locally relapsed or metastatic tumor receiving crania

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Treatment of cerebral or extracerebral recurrence or metastatic tumor using stereotactic radiotherapy AND parallel treatment with targeted therapy (antibodies, small molecule drugs, immunotherapy). Female and male subjects older than 18 years old

Exclusion criteria

Exclusion criteria: Written or oral revocation of the informed consent for the storage and processing of patient data

Design outcomes

Primary

Measure	Time frame
Early (12 weeks) and late (12 months) severe toxicity grade >= II according to CTCAE v4.0 of SRT-treatment concurrently combined with any targeted drug.	—

Secondary

Measure	Time frame
Efficacy data of local control of the irradiated lesion, systemic disease progression, patterns of disease progression and overall survival.	—

Countries

Australia, Austria, Belgium, Germany, Netherlands, Switzerland

Contacts

Public ContactIlinca Popp

Universitätsklinikum Freiburg, Klinik für Strahlenheilkunde

ilinca.popp@uniklinik-freiburg.de+49 761 270-94620

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026